Book contents
- Frontmatter
- Contents
- List of contributors
- Acknowledgements
- 1 Introduction
- Section I Information problems
- Section II End of life care
- Section III Pregnant women and children
- Section IV Genetics and biotechnology
- Introduction
- 20 Organ transplantation
- 21 Regenerative medicine
- 22 Genetic testing and screening
- 23 Bio-banking
- 24 Behavioral genetics
- Section V Research ethics
- Section VI Health systems and institutions
- Section VII Using clinical ethics to make an impact in healthcare
- Section VIII Global health ethics
- Section IX Religious and cultural perspectives in bioethics
- Section X Specialty bioethics
- Index
- References
21 - Regenerative medicine
Published online by Cambridge University Press: 30 October 2009
Book contents
- Frontmatter
- Contents
- List of contributors
- Acknowledgements
- 1 Introduction
- Section I Information problems
- Section II End of life care
- Section III Pregnant women and children
- Section IV Genetics and biotechnology
- Introduction
- 20 Organ transplantation
- 21 Regenerative medicine
- 22 Genetic testing and screening
- 23 Bio-banking
- 24 Behavioral genetics
- Section V Research ethics
- Section VI Health systems and institutions
- Section VII Using clinical ethics to make an impact in healthcare
- Section VIII Global health ethics
- Section IX Religious and cultural perspectives in bioethics
- Section X Specialty bioethics
- Index
- References
Summary
A 56-year-old man with severe angina pectoris visits a cardiac specialist for a consultation. During the course of the examination, the patient excitedly describes a story from the news about an experimental gene therapy that aims to stimulate new blood vessel growth in patients with coronary artery disease. He feels that such therapy could dramatically improve his condition and expresses a strong desire to enroll in the clinical trial. The clinician has some familiarity with the details of the trial and wonders how she should counsel her patient.
A 24-year-old woman with abnormal bladder development and function resulting from spina bifida visits her physician for a routine check-up. The patient would also like to discuss a new therapy she has heard about that involves the growth of a replacement bladder for transplantation using the patient's own cells. This therapy has been successfully applied in a number of other patients with spina bifida. Her physician wonders how to approach the discussion with his patient.
What is regenerative medicine?
Regenerative medicine has been the focus of substantial funding and research efforts worldwide (Attorney General of California, 2004; Greenwood et al., 2006). Additionally, it has engaged public attention through highly publicized political debates (Press, 2006; Wagner, 2006), media accounts of “miracle” cures (Kuntzman, 2004), and strong lobbying from voluntary health organizations (Perry, 2000). As a newly emerging and evolving field, there is to date no consensus definition of regenerative medicine (Mironov et al., 2004).
Information
- Type
- Chapter
- Information
- The Cambridge Textbook of Bioethics , pp. 153 - 159Publisher: Cambridge University PressPrint publication year: 2008
References
(2003). Ethical issues in organ and tissue transplantation. Exp Clin Transplant 1: 125–38.Google ScholarPubMed
2004. Ottawa: Department of Justice.
, , , , and (2006). Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 367: 1241–6.CrossRefGoogle ScholarPubMed
(2004). Stem Cell Research. Funding. Bonds. State of California. Sacramento, CA: Secretary of State of California.Google Scholar
(2005). Cloning in America: the Genetics and Public Policy Center surveys the nation. Genewatch 18: 13–18.Google ScholarPubMed
(2002). Stem Cells and the Future of Regenerative Medicine. Washington, DC: National Academy Press.Google Scholar
(2006). Stem Cell Research and Enhancement Act of 2005. Washington, DC: Library of Congress.Google Scholar
(2005). Stem cells, tissue engineering and organogenesis in transplantation. Transplant Immunol 15: 81–9.CrossRefGoogle ScholarPubMed
Daar, A. S. (2005). Regenerative medicine: a taxonomy for addressing ethical, legal and social issues. In Ethical, Legal and Social Issues in Organ Transplantation, ed. , , , and . Munich: PABST, pp. 368–77.Google Scholar
, , , et al. (2006). Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA 103: 5054–9.CrossRefGoogle Scholar
(2005). Consultation Paper: Human Tissue Engineering and Beyond: Proposal for a Community Regulatory Framework on Advanced Therapies. Brussels: European Commission, Enterprise and Industry Directorate-General.Google Scholar
, , , et al. (2006). Regenerative medicine: new opportunities for developing countries. Int J Biotechnol 8: 60–77.CrossRefGoogle Scholar
(2001). The emergence of regenerative medicine: a new field and a new society. J Regen Med 2: 17.Google Scholar
, , and (2005). Values in Conflict: Public Attitudes on Embryonic Stem Cell Research. Washington, DC: Genetics and Public Policy Center.Google Scholar
(2001). London: The Stationery Office for the Office of Public Sector Information.
, , , and (2004). Legal and ethical approaches to stem cell and cloning research: a comparative analysis of policies in Latin America, Asia, and Africa. J Law Med Ethics 32: 626–40.CrossRefGoogle ScholarPubMed
(2003). An overview of recent developments in the European regulation of medicine/medical device combination products. Drug Inform J 37: 39–43.CrossRefGoogle Scholar
(2005). Recent developments in gene transfer: risks and ethics. BMJ 330: 79–82.CrossRefGoogle Scholar
and (2004). Tissue engineering, stem cells, and cloning: opportunities for regenerative medicine. J Am Soc Nephrol 15: 1113–25.CrossRefGoogle ScholarPubMed
, , and (1999). Prospects for the use of nuclear transfer in human transplantation. Nat Biotechnol 17: 1171–4.CrossRefGoogle ScholarPubMed
, , , et al. (2005). A new era in the ethics of human embryonic stem cell research. Stem Cells 23: 1454–9.CrossRefGoogle ScholarPubMed
MBBNet (2007). http://mbbnet.umn.edu/scmap.html.
and (2003). Introducing new technologies: protecting subjects of surgical innovation and research. World J Surg 27: 930–5.CrossRefGoogle ScholarPubMed
and (2005). Enhancement technologies and professional integrity. Am J Bioethics 5: 15–17.CrossRefGoogle ScholarPubMed
, , and (2004). What is regenerative medicine? Emergence of applied stem cell and developmental biology. Expert Opin Biol Ther 4: 773–81.CrossRefGoogle ScholarPubMed
(2005). Biosafety law brings stem-cell research to Brazil. Nature 434: 128.CrossRefGoogle ScholarPubMed
(2004). Public opinion about stem cell research and human cloning. Pub Opin Q 68: 131–54.CrossRefGoogle Scholar
(2000). Patients' voices: the powerful sound in the stem cell debate. Science 287: 1423.CrossRefGoogle ScholarPubMed
(2005). Bringing safe and effective cell therapies to the bedside. Nat Biotechnol 23: 801–4.CrossRefGoogle Scholar
(2004). The case against perfection: what'swrong with designer children, bionic athletes, and genetic engineering. Atlantic Month 292: 50–4, 56–60, 62.Google ScholarPubMed
, , , et al. (2006). Dual release of proteins from porous polymeric scaffolds. J Contr Release 111: 95–106.CrossRefGoogle ScholarPubMed
(2005). UK Stem Cell Initiative. London: Government Printing Office (http://www.advisorybodies.doh.gov.uk/uksci/global/italy.htm).Google Scholar
(2004). Overview of the Office of Combination Products. Rockville, MD: US Food and Drug Administration (http://www.fda.gov/oc/combination/overview.html).Google Scholar
(2005). Good Tissue Practices Final Rule. Rockville, MD: US Food and Drug Administration.Google Scholar
(2001). Stem Cell Research. Washington, DC: Government Printing Office (http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html).Google Scholar
(2002). Treatment, enhancement, and the ethics of neurotherapeutics. Brain Cogn 50: 387–95.CrossRefGoogle ScholarPubMed
Accessibility standard: Unknown
Why this information is here
This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.Accessibility Information
Accessibility compliance for the PDF of this chapter is currently unknown
and may be updated in the future.